Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Arko Corp. (ARKO) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance

Arko Corp.Trade
Bio-Rad Laboratories, Inc. Class A Common StockTrade

Price performance (Past 24H)

Key statistics

Arko Corp. vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Arko Corp. trades at $4.39 (market cap $493.06M), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 19.1× Arko Corp.'s market cap, and Arko Corp. pays a 2.73% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.

ARKOBIO
Market Cap
$493.06M$9.43B
Sector
Consumer CyclicalHealth
52-Week High
$8.64$356.25
52-Week Low
$3.82$241.71
Enterprise Value
$2.67B$9.18B
Dividend Yield
2.73%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Arko Corp.

ARKO Corp operates as a holding company. The company, through its subsidiaries, owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in three segments: Retail, Wholesale, and GPM Petroleum. The company derives the majority of its revenue from retail and wholesale distribution of fuel.

Read more on ARKO

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO